TG Therapeutics, Inc.
TGTX
$42.54
-$0.60-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 700.35M | 616.29M | 531.90M | 454.07M | 386.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 700.35M | 616.29M | 531.90M | 454.07M | 386.39M |
| Cost of Revenue | 118.68M | 100.71M | 77.97M | 59.22M | 48.59M |
| Gross Profit | 581.67M | 515.57M | 453.93M | 394.85M | 337.80M |
| SG&A Expenses | 269.92M | 232.03M | 208.25M | 186.85M | 170.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 550.85M | 492.96M | 429.12M | 368.22M | 326.57M |
| Operating Income | 149.50M | 123.32M | 102.78M | 85.85M | 59.82M |
| Income Before Tax | 122.29M | 107.39M | 87.75M | 66.11M | 41.74M |
| Income Tax Expenses | -339.61M | -339.79M | -359.72M | 5.65M | 2.59M |
| Earnings from Continuing Operations | 461.90 | 447.18 | 447.47 | 60.46 | 39.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 461.90M | 447.18M | 447.47M | 60.46M | 39.15M |
| EBIT | 149.50M | 123.32M | 102.78M | 85.85M | 59.82M |
| EBITDA | 149.58M | 123.38M | 102.83M | 85.89M | 59.87M |
| EPS Basic | 3.18 | 3.08 | 3.08 | 0.41 | 0.27 |
| Normalized Basic EPS | 0.57 | 0.46 | 0.38 | 0.28 | 0.18 |
| EPS Diluted | 2.86 | 2.77 | 2.78 | 0.37 | 0.24 |
| Normalized Diluted EPS | 0.51 | 0.42 | 0.34 | 0.26 | 0.16 |
| Average Basic Shares Outstanding | 579.56M | 581.80M | 584.08M | 583.76M | 581.75M |
| Average Diluted Shares Outstanding | 642.99M | 645.69M | 646.57M | 646.29M | 643.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |